MA53400A - Hétéromultimères alk7: actriib et leurs utilisations - Google Patents

Hétéromultimères alk7: actriib et leurs utilisations

Info

Publication number
MA53400A
MA53400A MA053400A MA53400A MA53400A MA 53400 A MA53400 A MA 53400A MA 053400 A MA053400 A MA 053400A MA 53400 A MA53400 A MA 53400A MA 53400 A MA53400 A MA 53400A
Authority
MA
Morocco
Prior art keywords
actriib
alk7 heteromultimers
alk7
heteromultimers
Prior art date
Application number
MA053400A
Other languages
English (en)
Inventor
Roselyne Castonguay
Yossi Dagon
Asya Grinberg
John Knopf
Ravindra Kumar
Gang Li
Robert Scott Pearsall
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MA53400A publication Critical patent/MA53400A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
MA053400A 2015-04-06 2016-04-06 Hétéromultimères alk7: actriib et leurs utilisations MA53400A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562143579P 2015-04-06 2015-04-06

Publications (1)

Publication Number Publication Date
MA53400A true MA53400A (fr) 2021-08-04

Family

ID=57072866

Family Applications (4)

Application Number Title Priority Date Filing Date
MA054328A MA54328A (fr) 2015-04-06 2016-04-06 Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA053400A MA53400A (fr) 2015-04-06 2016-04-06 Hétéromultimères alk7: actriib et leurs utilisations
MA041916A MA41916A (fr) 2015-04-06 2016-04-06 Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA41920A MA41920B1 (fr) 2015-04-06 2016-04-06 Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA054328A MA54328A (fr) 2015-04-06 2016-04-06 Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA041916A MA41916A (fr) 2015-04-06 2016-04-06 Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA41920A MA41920B1 (fr) 2015-04-06 2016-04-06 Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations

Country Status (15)

Country Link
US (7) US10227392B2 (fr)
EP (4) EP3280435B1 (fr)
JP (3) JP7055636B2 (fr)
KR (2) KR20180002659A (fr)
CN (4) CN114736307A (fr)
AU (4) AU2016246708B2 (fr)
BR (1) BR112017021510A2 (fr)
CA (2) CA2981833A1 (fr)
DK (1) DK3280728T3 (fr)
EA (2) EA202190016A1 (fr)
ES (1) ES2863564T3 (fr)
HK (4) HK1248735A1 (fr)
MA (4) MA54328A (fr)
MX (1) MX2017012846A (fr)
WO (2) WO2016164089A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
KR20170141215A (ko) 2015-04-06 2017-12-22 악셀레론 파마 인코포레이티드 싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도
MA54328A (fr) 2015-04-06 2021-10-06 Acceleron Pharma Inc Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
RU2733492C2 (ru) 2015-04-22 2020-10-02 Байоджен Ма Инк. Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
EP3331550B1 (fr) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition pour le traitement de syndrome myéloprolifératif
CN105254764A (zh) * 2015-08-27 2016-01-20 上海康岱生物医药技术有限公司 ACVR1-Fc融合蛋白及其制法和用途
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
SI3496739T1 (sl) 2016-07-15 2021-06-30 Acceleron Pharma Inc. Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije
CA3039074A1 (fr) * 2016-10-05 2018-04-12 Acceleron Pharma Inc. Compositions et methode pour le traitement de la renopathie
JP7219705B2 (ja) 2016-10-05 2023-02-08 アクセルロン ファーマ インコーポレイテッド ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
WO2018067874A1 (fr) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Protéines actriib à variant et leurs utilisations
US11440949B2 (en) 2016-10-05 2022-09-13 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
KR20240046620A (ko) 2016-11-17 2024-04-09 2세븐티 바이오, 인코포레이티드 TGFβ 신호 컨버터
KR20190115037A (ko) * 2017-02-01 2019-10-10 악셀레론 파마 인코포레이티드 면역 활성을 증가시키는데 이용되는 TGFβ 및 ActRII
BR112019023071A2 (pt) 2017-05-04 2020-06-09 Acceleron Pharma Inc proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
EP3424957A1 (fr) * 2017-07-03 2019-01-09 advanceCOR GmbH Protéine de fusion
RU2020117439A (ru) * 2017-11-02 2021-12-02 Байер Акциенгезельшафт БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ALK-1 и BMPR-2
JP2021512919A (ja) * 2018-02-09 2021-05-20 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
CA3093078A1 (fr) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Recepteurs d'antigene chimerique specifique a l'antigene prostatique specifique membranaire et leurs procedes d'utilisation
JP2021522793A (ja) * 2018-05-03 2021-09-02 アクセルロン ファーマ インコーポレイテッド ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用
EP3788067A4 (fr) * 2018-05-03 2022-01-19 Acceleron Pharma Inc. Nouveaux liants de ligands de la superfamille des tgfbêta et leurs utilisations
JP7405772B2 (ja) * 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
WO2019226658A1 (fr) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation
CA3099308A1 (fr) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions et procedes pour ameliorer la destruction de cellules cibles par des lymphocytes nk
US20220089683A1 (en) * 2018-06-15 2022-03-24 Acceleron Pharma Inc. Bi-and tri-functional fusion proteins and uses thereof
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
KR20230002391A (ko) * 2020-03-13 2023-01-05 악셀레론 파마 인코포레이티드 신장 질환 또는 병태를 치료하기 위한 단일-가지 actriia 및 actriib 이종다량체 및 치료 방법
CN115768457A (zh) * 2020-03-20 2023-03-07 科乐斯疗法公司 激活素受体ii型嵌合体以及其使用方法
KR102587871B1 (ko) * 2020-06-19 2023-10-12 숙명여자대학교산학협력단 Bmpr2 유전자 기능획득 돌연변이체를 포함하는 돌연변이 복합체 및 이의 용도
CA3196443A1 (fr) * 2020-11-04 2022-05-12 Hq Han Nouveaux antagonistes multispecifiques bifonctionnels capables d'inhiber de multiples ligands de la famille du tgf-beta et utilisations correspondantes
WO2024182505A1 (fr) * 2023-03-01 2024-09-06 The Regents Of The University Of California Utilisation d'inhibiteurs alk1 du récepteur bmp dans des thérapies contre l'arthrose

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
EP1493825A3 (fr) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Procédé pour la production de ligands constitués par des acides nucléiques
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US20050186593A1 (en) * 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
DE69332779T2 (de) 1992-11-17 2003-10-23 Ludwig Institut For Cancer Research, Padington Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5614609A (en) 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU716893B2 (en) 1995-04-11 2000-03-09 General Hospital Corporation, The Reverse two-hybrid systems
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
JPH10303327A (ja) 1997-04-23 1998-11-13 Yamaichi Electron Co Ltd 半導体チップの接点変換構造と該接点変換構造を有する半導体チップの製造法
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6011577A (en) 1997-06-30 2000-01-04 Polaroid Corporation Modular optical print head assembly
JP2001513982A (ja) 1997-08-29 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド フォリスタチン−３
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (fr) 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
WO2000039585A1 (fr) 1998-12-28 2000-07-06 Sunesis Pharmaceuticals, Inc. Identification de ligands de type petites molecules organiques, destines a former des liaisons
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
DE60042021D1 (de) 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
EP1272647B1 (fr) 2000-04-11 2014-11-12 Genentech, Inc. Anticorps multivalents et leurs utilisations
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
CA2488441C (fr) 2002-06-03 2015-01-27 Genentech, Inc. Bibliotheques de phages et anticorps synthetiques
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2004065416A2 (fr) 2003-01-16 2004-08-05 Genentech, Inc. Banques de phages anticorps synthetiques
WO2005025601A1 (fr) 2003-09-15 2005-03-24 Monash University Isoformes de follistatine et leurs utilisations
DK1670511T3 (da) 2003-09-15 2009-11-23 Res Dev Foundation Cripto-antagonisme af activin- og TGF-B-signalering
EP3006039B1 (fr) * 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides pour stimuler la perte de graisse
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2360186B1 (fr) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anticorps dirigés contre la sélectine P
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CA2580141C (fr) 2004-09-23 2013-12-10 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
EP1957531B1 (fr) 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
CN101370511B (zh) * 2005-11-23 2015-07-01 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
CN105001320A (zh) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
AU2007254824A1 (en) * 2006-06-02 2007-12-13 Wyeth Use of proteins and peptides of the TGF-beta superfamily for purification and therapeutic methods
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
WO2008030367A2 (fr) 2006-09-01 2008-03-13 The General Hospital Corporation Inhibiteurs sélectifs de la myostatine
CN111518218A (zh) * 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
AU2007332819A1 (en) 2006-12-08 2008-06-19 Acceleron Pharma Inc. Uses of cerberus, coco and derivatives thereof
MX2009006651A (es) * 2006-12-18 2009-08-26 Acceleron Pharma Inc Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojo.
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
EP2574671B1 (fr) 2007-03-19 2016-02-03 National Research Council Of Canada Antagonistes de ligands et leurs utilisations
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
MX2010011998A (es) * 2008-05-02 2011-04-11 Acceleron Pharma Inc Metodos y composiciones de pericitos para regular la angiogenesis y composicion de pericapilar.
TWI748373B (zh) 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
CA2737271C (fr) 2008-09-17 2020-06-23 National Research Council Of Canada Agents de liaison hetero-multivalents pour des membres de la superfamille des tgf.beta.
LT2370463T (lt) * 2008-11-26 2016-12-12 Amgen Inc. Stabilizuotas aktivino iib receptoriaus variantas
EP2387412A4 (fr) 2009-01-13 2013-04-03 Acceleron Pharma Inc Procédés permettant d'augmenter l'adiponectine
US8338377B2 (en) * 2009-03-30 2012-12-25 Acceleron Pharma Inc. BMP-ALK3 antagonists and uses for promoting bone growth
EP3805259A1 (fr) 2009-06-12 2021-04-14 Acceleron Pharma Inc. Protéines de fusion actriib-fc tronquées
CA2781519A1 (fr) 2009-09-16 2011-03-24 Genentech, Inc. Complexes proteiques contenant une super-helice et/ou une attache et leurs utilisations
FR2951408B1 (fr) 2009-10-15 2012-01-13 Renault Sa Cadre moteur pour moteur electrique de vehicule automobile
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012027065A2 (fr) 2010-08-27 2012-03-01 Celgene Corporation Polythérapie pour traiter des maladies
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
WO2013063536A1 (fr) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. AGENTS DE LIAISON À ActRIIB ET UTILISATIONS DE CEUX-CI
EP2831105B1 (fr) 2012-03-28 2017-08-09 The Board of Regents of The University of Texas System Fusions du récepteur de tgf de type ii-type iii
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
WO2016090035A2 (fr) 2014-12-02 2016-06-09 La Jolla Institute For Allergy And Immunology Modulateurs de l'activine et procédés de modulation de réponses immunitaires et de cellules t auxiliaires folliculaires
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
MA54328A (fr) 2015-04-06 2021-10-06 Acceleron Pharma Inc Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
KR20170141215A (ko) 2015-04-06 2017-12-22 악셀레론 파마 인코포레이티드 싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도
RU2733492C2 (ru) 2015-04-22 2020-10-02 Байоджен Ма Инк. Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
WO2016205370A1 (fr) 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Méthodes d'utilisation de protéines à base du récepteur iib de l'activine
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
WO2018009624A1 (fr) 2016-07-07 2018-01-11 Acceleron Pharma Inc. Hétéromultimères de la superfamille tgf-bêta et leurs utilisations
WO2018009732A1 (fr) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anticorps anti-activine a et méthodes d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
JP7219705B2 (ja) 2016-10-05 2023-02-08 アクセルロン ファーマ インコーポレイテッド ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

Also Published As

Publication number Publication date
AU2016244750B2 (en) 2021-02-18
CA2981737A1 (fr) 2016-10-13
JP7055636B2 (ja) 2022-04-18
CA2981833A1 (fr) 2016-10-13
MA54328A (fr) 2021-10-06
EP3889171A1 (fr) 2021-10-06
BR112017021510A2 (pt) 2018-07-03
EP3280728B1 (fr) 2020-12-16
HK1248733A1 (zh) 2018-10-19
WO2016164503A1 (fr) 2016-10-13
US20220396607A1 (en) 2022-12-15
CN107847561A (zh) 2018-03-27
EP3280435A4 (fr) 2018-12-19
EP3280728A4 (fr) 2018-09-12
KR20180002659A (ko) 2018-01-08
MX2017012846A (es) 2018-11-09
CN107709358A (zh) 2018-02-16
JP2021104057A (ja) 2021-07-26
US11028145B2 (en) 2021-06-08
MA41920A (fr) 2018-02-14
AU2016246708A1 (en) 2017-10-26
US20220119491A1 (en) 2022-04-21
WO2016164089A3 (fr) 2016-12-08
EA037293B1 (ru) 2021-03-05
AU2020281136A1 (en) 2021-01-07
AU2016246708B2 (en) 2020-12-24
EP3280728A1 (fr) 2018-02-14
AU2021200492A1 (en) 2021-02-25
US20190375820A1 (en) 2019-12-12
CN107847561B (zh) 2022-03-29
US20160297867A1 (en) 2016-10-13
HK1252957A1 (zh) 2019-06-06
JP2018513147A (ja) 2018-05-24
US10227392B2 (en) 2019-03-12
EA201792222A1 (ru) 2018-04-30
KR20180002661A (ko) 2018-01-08
MA41920B1 (fr) 2021-05-31
DK3280728T3 (da) 2021-03-01
CN114736307A (zh) 2022-07-12
CN115073610A (zh) 2022-09-20
JP7246618B2 (ja) 2023-03-28
MA41916A (fr) 2021-04-14
JP7037363B2 (ja) 2022-03-16
US10906958B2 (en) 2021-02-02
EA202190016A1 (ru) 2021-08-31
HK1250373A1 (zh) 2018-12-14
HK1248735A1 (zh) 2018-10-19
US10227393B2 (en) 2019-03-12
US11827689B2 (en) 2023-11-28
ES2863564T3 (es) 2021-10-11
JP2018517399A (ja) 2018-07-05
AU2016244750A1 (en) 2017-10-26
EP3280435A2 (fr) 2018-02-14
US20190225669A1 (en) 2019-07-25
US20240158468A1 (en) 2024-05-16
EP3828199A1 (fr) 2021-06-02
EP3280435B1 (fr) 2021-06-02
WO2016164089A2 (fr) 2016-10-13
US20160298093A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
FR24C1023I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA55044A (fr) Hétéromultimères alk4:actriib et leurs utilisations
MA46472A (fr) Hétéromultimères alk4:actriib et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA56480A (fr) Agonistes du récepteur glp-1 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA43529A (fr) Modulateurs de transport nucléaire et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
MA46700A (fr) Variants polypeptidiques et ses utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations